ArticleChinese journal of integrative medicine2026
Cardioprotective Effects of Ling-Gui-Zhu-Gan Decoction Against Ventricular Remodeling after Acute Myocardial Infarction via ROS/TXNIP/NLRP3 Signaling.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the underlying mechanism of Ling-Gui-Zhu-Gan Decoction (LGZGD) in reducing hyperinflammatory responses to provide cardioprotective effects.
methodsThe main chemical components of LGZGD were identified using ultra-high performance liquid chromatography. In vivo, the rats were randomly divided into 4 groups using simple randomization: the sham group, the model group, the LGZGD (4.2 g/kg) group, and captopril (4.375 mg/kg) group, 6 in each group. A rat model of ventricular remodeling (VR) after acute myocardial infarction (AMI) was established by ligation of the left anterior descending coronary artery. After 4 weeks of treatment, cardiac function was evaluated by echocardiography, and histopathological changes were examined using HE and Masson stainings. Serum levels of cardiac enzymes and oxidative stress markers were measured with microplate assays. Reactive oxygen species (ROS) were visualized by fluorescence staining, while protein and mRNA levels were analyzed by Western blot and RT-qPCR. Levels of proinflammatory cytokines and trimethylamine N-oxide (TMAO) were quantified through ELISA. In vitro, H9c2 cells were exposed to 400 µmol/L TMAO, and oxidative stress markers were measured by microplate assay. ROS levels were visualized using fluorescence staining, and gene and protein expression were analyzed by RT-PCR and Western blot. Proinflammatory cytokines and TMAO levels were further evaluated by ELISA.
resultsLGZGD was found to contain liquiritin, isoliquiritin, coumarin, liquiritigenin, cinnamic acid, kaempferol, cinnamaldehyde, glycyrrhizic acid, and atractylenolide III. In vivo, LGZGD improved cardiac function, reduced myocardial pathology, lowered serum cardiac enzymes and TMAO, decreased oxidative stress, regulated the expression of genes and proteins within the ROS/thioredoxin-interacting protein (TXNIP)/NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) pathway, and suppressed the secretion of IL-1β and IL-18 (P<0.01). In vitro analysis showed that LGZGD significantly decreased markers of myocardial injury, alleviated oxidative stress, and inhibited the secretion of IL-1β and IL-18 in TMAO-stimulated H9c2 cells (P<0.01).
conclusionLGZGD ameliorates TMAO-induced myocardial injury by modulating the ROS/TXNIP/NLRP3 signaling pathway.
Indexed as
Identifiers
41793649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.